These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 9509267)

  • 1. Adoptive immunotherapy following allogeneic bone marrow transplantation.
    Dazzi F; Goldman JM
    Annu Rev Med; 1998; 49():329-40. PubMed ID: 9509267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The graft-versus-leukemia effects of allogeneic cell therapy.
    Porter DL; Antin JH
    Annu Rev Med; 1999; 50():369-86. PubMed ID: 10073284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies.
    Naparstek E; Nagler A; Or R; Kapelushnik J; Slavin S
    Clin Transpl; 1996; ():281-90. PubMed ID: 9286578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD28/B7 interactions are required for sustaining the graft-versus-leukemia effect of delayed post-bone marrow transplantation splenocyte infusion in murine recipients of myeloid or lymphoid leukemia cells.
    Blazar BR; Taylor PA; Boyer MW; Panoskaltsis-Mortari A; Allison JP; Vallera DA
    J Immunol; 1997 Oct; 159(7):3460-73. PubMed ID: 9317145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cellular immunotherapy in chronic myeloid leukemia].
    Fernández MN
    Sangre (Barc); 1998 Apr; 43(2):164-70. PubMed ID: 9656778
    [No Abstract]   [Full Text] [Related]  

  • 6. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes.
    Slavin S; Naparstek E; Nagler A; Ackerstein A; Kapelushnik J; Or R
    Exp Hematol; 1995 Dec; 23(14):1553-62. PubMed ID: 8542946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2.
    Weiss L; Lubin I; Factorowich I; Lapidot Z; Reich S; Reisner Y; Slavin S
    J Immunol; 1994 Sep; 153(6):2562-7. PubMed ID: 8077666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adoptive immunotherapy using donor leukocytes following bone marrow transplantation for chronic myeloid leukemia: is T cell dose important in determining biological response?
    Mackinnon S; Papadopoulos EB; Carabasi MH; Reich L; Collins NH; O'Reilly RJ
    Bone Marrow Transplant; 1995 Apr; 15(4):591-4. PubMed ID: 7655386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease.
    Johnson BD; Drobyski WR; Truitt RL
    Bone Marrow Transplant; 1993 Apr; 11(4):329-36. PubMed ID: 8485480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: impact of infused and residual donor T cells.
    Verdonck LF; Petersen EJ; Lokhorst HM; Nieuwenhuis HK; Dekker AW; Tilanus MG; de Weger RA
    Bone Marrow Transplant; 1998 Dec; 22(11):1057-63. PubMed ID: 9877267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adoptive immunotherapy for relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: equal efficacy of lymphocytes from sibling and matched unrelated donors.
    van Rhee F; Savage D; Blackwell J; Orchard K; Dazzi F; Lin F; Chase A; Bungey J; Cross NC; Apperley J; Szydlo R; Goldman JM
    Bone Marrow Transplant; 1998 May; 21(10):1055-61. PubMed ID: 9632281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Donor lymphocyte infusions (DLI) in patients with chronic myeloid leukemia following allogeneic bone marrow transplantation.
    Bacigalupo A; Soracco M; Vassallo F; Abate M; Van Lint MT; Gualandi F; Lamparelli T; Occhini D; Mordini N; Bregante S; Figari O; Benvenuto F; Sessarego M; Fugazza G; Carlier P; Valbonesi M
    Bone Marrow Transplant; 1997 May; 19(9):927-32. PubMed ID: 9156268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Alloreactive donor lymphocytes (DLI) after allogeneic hematopoietic stem cell transplantation (HSCT): study of toxicity and efficacy].
    Michallet AS; Nicolini F; Michallet M
    Bull Cancer; 2003; 90(8-9):758-62. PubMed ID: 14609766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy of relapsed resistant chronic myelogenous leukemia post allogeneic bone marrow transplantation with alloantigen pulsed donor lymphocytes.
    Slavin S; Ackerstein A; Morecki S; Gelfand Y; Cividalli G
    Bone Marrow Transplant; 2001 Oct; 28(8):795-8. PubMed ID: 11781634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Donor T-lymphocyte infusion for unrelated allogeneic bone marrow transplantation with CD3+ T-cell-depleted graft.
    Lee CK; deMagalhaes-Silverman M; Hohl RJ; Hayashi M; Buatti J; Wen BC; Schlueter A; Strauss RG; Gingrich RD
    Bone Marrow Transplant; 2003 Jan; 31(2):121-8. PubMed ID: 12621494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alloreactivity and the predictive value of anti-recipient specific interleukin 2 producing helper T lymphocyte precursor frequencies for alloreactivity after bone marrow transplantation.
    Russell CA
    Dan Med Bull; 2002 May; 49(2):89-108. PubMed ID: 12064093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Graft-versus-leukemia effects from donor lymphocyte infusion after nonmyeloablative allogeneic bone marrow transplantation in mice.
    Du B; Li DP; Xu KL; Pan XY
    Chin Med J (Engl); 2005 Mar; 118(6):474-9. PubMed ID: 15788128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular basis for therapeutic decisions in chronic myeloid leukemia patients after allogeneic bone marrow transplantation.
    Román J; Alvarez MA; Torres A
    Haematologica; 2000 Oct; 85(10):1072-82. PubMed ID: 11025600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Minimal residual disease after bone marrow transplantation for chronic myelogenous leukemia and implications for graft-versus-leukemia effect: a review of recent results.
    Miyamura K; Barrett AJ; Kodera Y; Saito H
    Bone Marrow Transplant; 1994 Aug; 14(2):201-9. PubMed ID: 7994233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune escape from a graft-versus-leukemia effect may play a role in the relapse of myeloid leukemias following allogeneic bone marrow transplantation.
    Dermime S; Mavroudis D; Jiang YZ; Hensel N; Molldrem J; Barrett AJ
    Bone Marrow Transplant; 1997 May; 19(10):989-99. PubMed ID: 9169643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.